Quince Therapeutics, Inc. (IRLA): Total Liabilities
$129.24M
As of 2025-12-31
$15.51M
As of 2026-06-30
+239.0%
3-year compound annual growth
+49.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $129.24M | +53.2% | 2026-04-10, Balance as of period end |
| 2024-12-31 | $84.33M | +1.8% | 2026-04-10, Balance as of period end |
| 2023-12-31 | $82.82M | n/m | 2025-03-24, Balance as of period end |
| 2022-12-31 | $3.32M | -77.3% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $14.64M | -14.9% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $17.20M | +93.5% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $8.89M | +510.3% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $1.46M | n/a | 2020-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (IRLA) | 2025-12-31 | $129.24M | +53.2% |
| LeonaBio, Inc. (LONA) | 2025-12-31 | $64.36M | +361.8% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $286.49M | +310.2% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $34.99M | -64.7% |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | $8.95M | -41.5% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $34.12M | +12.9% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $295.48M | +119.8% |
Compare IRLA, LONA, SRZN, ALGS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗